Study identifier:NIS-NHU-SER-2010/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Seroquel XR in the long term treatment of schizophrenia focus on affective symptoms
relapse in schizophrenia
-
No
-
All
1606
Observational
18 Years - 70 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improves the relapse prevention in schizophrenic outpatients
Location
Location
Baja, Hungary
Location
Balassagyarmat, Hungary
Location
Barcs, Hungary
Location
Berettyoujfalu, Hungary
Location
Budapest, Hungary
Location
Cegled, Hungary
Location
Csongrad, Hungary
Location
Debrecen, Hungary
Arms | Assigned Interventions |
---|---|
Schizophrenic outpatients between 18 & 70 years of age | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.